- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01728285
Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis (GT-17)
November 14, 2012 updated by: ALK-Abelló A/S
A Multicentric Open Randomised, Cross-over Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
Adherence to treatment is crucial to the efficacy of sublingual immunotherapy of allergic diseases.
GRAZAX® is a registered drug in Europe, with established efficacy in the treatment of allergic rhinitis, which has to be taken daily by patients.
This study was aimed to establish if a device with the characteristics of a mechanical dispenser (Memozax®) could improve adherence to treatment in subjects with hay fever due to allergy to grass
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
261
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
PV
-
Pavia, PV, Italy, 27100
- Fondazione IRCCS Policlinico San Matteo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A clinical history of grass pollen-induced allergic rhinoconjunctivitis (with or without asthma) having received treatment during the previous grass pollen season.
- Positive skin prick test (SPT) response (wheal diameter ≥3mm) to Phleum pratense
- Positive specific IgE against Phleum pratense (IgE titer > class 2)
Exclusion Criteria:
- Clinical history of chronic sinusitis during the last 2 years or of symptomatic perennial or seasonal allergic rhinitis and/or asthma having received regular medication, due to another allergen during - or potentially overlapping - the grass pollen season.
- Clinical history of severe asthma (GINA Step 4 and children with Forced Expiratory Volume in 1 second (FEV1) < 80% of expected value after treatment with inhaled corticosteroids and short-acting β2 agonists)
- Previous treatment by immunotherapy with grass pollen allergen or any other allergen within the previous 5 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Electronic compliance device
Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) using an electronic compliance device (Memozax®)
|
An electronic compliance device is distributed to patients allocated to the active arm
|
No Intervention: No electronic compliance device
Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) without any electronic compliance device (Memozax®)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate if compliance with grass Allergy Immunotherapy Tablet can be increased by providing an electronic compliance device (CED) (Memozax; a tablet-container with a programmable daily acoustic alarm)
Time Frame: up to 1 year per patient
|
To evaluate if compliance of once daily dosing with Grazax in adult subjects with grass pollen induced allergic rhinoconjunctivitis can be increased by providing patients with an electronic compliance device.
Compliance in the two groups (with Memozax and without Memozax) was evaluated by tablet counts
|
up to 1 year per patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of GRAZAX® treatment on QoL as compared to previous season
Time Frame: up to 1 year per patient
|
To evaluate after one-year treatment with Grazax tablets the impact on quality of life in comparison with previous pollen seasons
|
up to 1 year per patient
|
Impact of GRAZAX® treatment on allergy symptoms as compared to previous season
Time Frame: up to 1 year per patient
|
To evaluate after one-year treatment with Grazax tablets the impact on symptom score in comparison with previous pollen seasons
|
up to 1 year per patient
|
Impact of GRAZAX® on treatment acceptance as compared to previous season
Time Frame: up to 1 year per patient
|
To evaluate after one-year treatment with Grazax tablets the impact on patient's acceptance in comparison with previous pollen seasons
|
up to 1 year per patient
|
Recording of all adverse events and serious adverse events
Time Frame: up to 1 year per patient
|
The safety assessments included recording of all adverse events (AE) and serious adverse events (SAE) findings from physical examinations and from vital signs
|
up to 1 year per patient
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
June 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
November 2, 2012
First Submitted That Met QC Criteria
November 14, 2012
First Posted (Estimate)
November 19, 2012
Study Record Updates
Last Update Posted (Estimate)
November 19, 2012
Last Update Submitted That Met QC Criteria
November 14, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GT-17 ITALY
- 2006-004820-35 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinitis
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Humanis Saglık Anonim SirketiCompletedPerennial Allergic Rhinitis | Seasonal Allergic RhinitisIndia
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
West Penn Allegheny Health SystemPennsylvania Allergy and Asthma Research FoundationCompletedAllergy | Perennial Allergic Rhinitis | Seasonal Allergic RhinitisUnited States
-
Ahn-Gook Pharmaceuticals Co.,LtdSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsCompletedAllergic Rhinitis | Perennial Allergic Rhinitis | Non-seasonal Allergic RhinitisKorea, Republic of
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
Clinical Trials on Electronic compliance device (Memozax®)
-
Kuopio University HospitalWithdrawnOpiate Dependence
-
Kuopio University HospitalUniversity of Eastern FinlandCompleted
-
Northwell HealthCompletedAutism Spectrum Disorder | Wandering BehaviorUnited States
-
Wicab Technologies (Beijing) Co., Ltd.Completed
-
Imperial College LondonAsthma UKCompletedAsthma in ChildrenUnited Kingdom
-
Duke UniversityRecruitingFluid OutputUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedCuff Overinflation | Cuff UnderinflationFrance
-
Xoft, Inc.Icad, Inc.CompletedCervical CancerUnited States
-
Assistance Publique - Hôpitaux de ParisTerminated